Exhibit 10.14
EXECUTED VERSION
CERTAIN INFORMATION CONTAINED IN THIS EXHIBIT, MARKED BY [***], HAS
BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE THE REGISTRANT HAS
DETERMINED THAT IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE
REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.
NON-EXCLUSIVE LICENSE AGREEMENT
This NON-EXCLUSIVE LICENSE AGREEMENT (“Agreement”) is entered into as of April 10, 2020 (“Effective Date”) between enGene, Inc., a corporation formed under Canadian law having its principal place of business at 7171 Frederick Banting, Suite 3232, Laurent, Quebec, Canada, H4S, 1Z9 (“ENGENE”) and Nature Technology Corporation, a Delaware corporation with a place of business at 4701 Innovation Drive, Suite 103, Lincoln, NE 68521 (“NTC”), each referred to herein individually as “Party” and collectively as “Parties.”
WHEREAS, NTC designs and develops gene encoded therapy vectors and methods for making such vectors;
WHEREAS, NTC is the owner of certain Patent Rights and Licensed Know-How (each defined below) regarding such vectors and methods and desires to grant a license to the same; and
WHEREAS, ENGENE is engaged in the development and commercialization of gene and cell therapy products and desires to license such Patent Rights and Licensed Know-How.
NOW, THEREFORE, in consideration of good and valuable consideration, the receipt and sufficiency of which are herein acknowledged, the Parties hereby agree as follows:
ARTICLE 1
DEFINITIONS
As used in this Agreement, the following terms shall have the meanings set out in this Article I unless otherwise specifically provided herein.
1.1 “Affiliate” with respect to either Party shall mean any corporation or other legal entity other than that Party in whatever country organized, controlling, controlled by or under common control with that Party. The term “control” shall mean direct or indirect ownership of fifty percent (50%) or more of the voting securities having the right to elect directors.
1.2 “Confidential Information” means, other than Exempt Information, all information, in whatever form or manner presented, which is disclosed or provided by or on behalf of the Disclosing Party to the Receiving Party during the Term and either (a) relates to the Disclosing Party’s business or business plans, including but not limited to suppliers, customers, prospective customers, contractors, pre-clinical or clinical data, grant proposals, the content and format of various clinical and medical databases, utilization data, cost and pricing data, disease management data, software products, programming techniques, data warehouse and methodologies, know-how, trade secrets, technical and non-technical materials, processes, sales and marketing plans and strategies, designs, and any discussions and proceedings relating to any of the foregoing, or (b) is information which a reasonable person would deem as confidential.